Which insulin regimens are used in patients newly-diagnosed with Type 1 diabetes? Results of an electronic survey of healthcare professionals in the UK and Ireland. Read more about Which insulin regimens are used in patients newly-diagnosed with Type 1 diabetes? Results of an electronic survey of healthcare professionals in the UK and Ireland.
Ward-based management of abnormal glucose levels with a multi-disciplinary team approach Read more about Ward-based management of abnormal glucose levels with a multi-disciplinary team approach
Improved clinical outcomes after embedding structured education for type 1 diabetes without additional manpower resource Read more about Improved clinical outcomes after embedding structured education for type 1 diabetes without additional manpower resource
Will empagliflozin reduce mortality in the real world? Read more about Will empagliflozin reduce mortality in the real world?
The Glycaemic Response to Dapagliflozin according to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit Read more about The Glycaemic Response to Dapagliflozin according to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit
Title Mortality, morbidity, weight and metabolic outcomes 15 years after very low calorie diet therapy in 325 persons. Read more about Title Mortality, morbidity, weight and metabolic outcomes 15 years after very low calorie diet therapy in 325 persons.
Insulin degludec improves minor, severe and nocuturnal hypoglycaemia in Type 1 diabetes: Association of British Clinical Diabetologists (ABCD) nationwide insulin degludec audit Read more about Insulin degludec improves minor, severe and nocuturnal hypoglycaemia in Type 1 diabetes: Association of British Clinical Diabetologists (ABCD) nationwide insulin degludec audit
Posters Autumn 2016 Read more about Posters Autumn 2016Log in or register to post comments An audit of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in a specialist community service: are the NICE Technology Appraisal (TA) guidelines too restrictive? Read more about An audit of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in a specialist community service: are the NICE Technology Appraisal (TA) guidelines too restrictive? GAVE a little, gain a lot Read more about GAVE a little, gain a lot Pagination First Previous … Page 131 Page 132 Page 133 Page 134 135 Page 136 Page 137 Page 138 Page 139 … Next Last Subscribe to The Association of British Clinical Diabetologists Main navigation About Reach and Representation Committee Member Memorial Overview Professional Development Events Submit an Abstract Webinars Event Archive Event Terms and Conditions Overview Resources Position Papers and Guidelines Joint British Diabetes Societies Rowan Hillson Awards Overview Audits ABCD Tirzepatide Audit ABCD and Sanofi DKA Collaborative Working Project ABCD Closed-Loop Audit ABCD NHS England Nationwide Closed Loop Pilot Audit ABCD Dexcom Audit ABCD FreeStyle Libre Audit ABCD Testosterone & Diabetes Worldwide Audit ABCD Oral Semaglutide Audit ABCD Semaglutide Audit ABCD EndoBarrier Worldwide Registry Audit Publications Grants Diabetes Dragons' Den Research Grants Travel Grants Overview DTN-UK About DTN-UK Join the Diabetes Technology Network UK (DTN-UK) Videos Resources Events Best Practice Guides and Top Tips Links to HCP education resources Committee Overview British Journal of Diabetes Search Search the Association of British Clinical Diabetologists Search User account menu Back to the ABCD Home page Become a member Log in
An audit of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in a specialist community service: are the NICE Technology Appraisal (TA) guidelines too restrictive? Read more about An audit of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in a specialist community service: are the NICE Technology Appraisal (TA) guidelines too restrictive?
